Recent advances in β-catenin/BCL9 protein–protein interaction inhibitors

Papers of special note have been highlighted as: • of interest; •• of considerable interest

References

• 1. Azzarito V, Long K, Murphy NS, Wilson AJ. Inhibition of α-helix-mediated protein–protein interactions using designed molecules. Nat. Chem. 5(3), 161–173 (2013).
  Medline CASGoogle Scholar
• 2. Stumpf MP, Thorne T, De Silva E et al. Estimating the size of the human interactome. Proc. Natl Acad. Sci. USA 105(19), 6959–6964 (2008).
  Medline CASGoogle Scholar
• 3. Venkatesan K, Rual JF, Vazquez A et al. An empirical framework for binary interactome mapping. Nat. Methods 6(1), 83–90 (2009).
  Medline CASGoogle Scholar
• 4. London N, Raveh B, Schueler-Furman O. Druggable protein–protein interactions – from hot spots to hot segments. Curr. Opin. Chem. Biol. 17(6), 952–959 (2013).
  Medline CASGoogle Scholar
• 5. Jones S, Thornton JM. Principles of protein–protein interactions. Proc. Natl Acad. Sci. USA 93(1), 13–20 (1996).
  Medline CASGoogle Scholar
• 6. Milroy L-G, Grossmann TN, Hennig S, Brunsveld L, Ottmann C. Modulators of protein–protein interactions. Chem. Rev., 114(9), 4695–4748 (2014).
  Medline CASGoogle Scholar
• 7. Ashkenazi A, Fairbrother WJ, Leverson JD et al. From basic apoptosis discoveries to advanced selective BCL-2 family inhibitors. Nat. Rev. Drug. Discov. 16(4), 273–284 (2017).
  Medline CASGoogle Scholar
• 8. Zhong M, Hanan EJ, Shen W et al. Structure–activity relationship (SAR) of the α-amino acid residue of potent tetrahydroisoquinoline (THIQ)-derived LFA-1/ICAM-1 antagonists. Bioorg. Med. Chem. Lett. 21(1), 307–310 (2011).
  Medline CASGoogle Scholar
• 9. Sheng C, Dong G, Miao Z, Zhang W, Wang W. State-of-the-art strategies for targeting protein-protein interactions by small-molecule inhibitors. Chem. Soc. Rev. 44(22), 8238–8259 (2015). • Valuable article reporting the importance of PPIs.
  Medline CASGoogle Scholar
• 10. Zhuang C, Miao Z, Sheng C, Zhang W. Updated research and applications of small molecule inhibitors of Keap1–Nrf2 protein–protein interaction: a review. Curr. Med. Chem. 21(16), 1861–1870 (2014).
  Medline CASGoogle Scholar
• 11. Van Andel H, Kocemba KA, Spaargaren M, Pals ST. Aberrant Wnt signaling in multiple myeloma: molecular mechanisms and targeting options. Leukemia 33(5), 1063–1075 (2019).
  Medline CASGoogle Scholar
• 12. Anthony CC, Robbins DJ, Ahmed Y, Lee E. Nuclear regulation of Wnt/β-catenin signaling: it’s a complex situation. Genes 11(8),886 (2020).
  CASGoogle Scholar
• 13. Gumbiner BM. Carcinogenesis: a balance between beta-catenin and APC. Curr. Biol. 7(7), R443–R446 (1997).
  Medline CASGoogle Scholar
• 14. Rubinfeld B, Albert I, Porfiri E, Fiol C, Munemitsu S, Polakis P. Binding of GSK3beta to the APC–beta-catenin complex and regulation of complex assembly. Science 272(5264), 1023–1026 (1996).
  Medline CASGoogle Scholar
• 15. Perugorria MJ, Olaizola P, Labiano I et al. Wnt–β-catenin signalling in liver development, health and disease. Nat. Rev. Gastroenterol. Hepatol. 16(2), 121–136 (2019).
  Medline CASGoogle Scholar
• 16. Tran FH, Zheng JJ. Modulating the Wnt signaling pathway with small molecules. Protein Sci. 26(4), 650–661 (2017).
  Medline CASGoogle Scholar
• 17. Cong F, Schweizer L, Varmus H. Wnt signals across the plasma membrane to activate the beta-catenin pathway by forming oligomers containing its receptors, Frizzled and LRP. Development 131(20), 5103–5115 (2004).
  Medline CASGoogle Scholar
• 18. Schwarz-Romond T, Fiedler M, Shibata N et al. The DIX domain of Dishevelled confers Wnt signaling by dynamic polymerization. Nat. Struct. Mol. Biol. 14(6), 484–492 (2007).
  Medline CASGoogle Scholar
• 19. Gao C, Chen YG. Dishevelled: the hub of Wnt signaling. Cell. Signal. 22(5), 717–727 (2010).
  Medline CASGoogle Scholar
• 20. Logan CY, Nusse R. The Wnt signaling pathway in development and disease. Annu. Rev. Cell. Dev. Biol. 20, 781–810 (2004).
  Medline CASGoogle Scholar
• 21. Clevers H, Nusse R. Wnt/β-catenin signaling and disease. Cell 149(6), 1192–1205 (2012). •• A comprehensive introduction of the Wnt pathway and its related diseases.
  Medline CASGoogle Scholar
• 22. He TC, Sparks AB, Rago C et al. Identification of c-MYC as a target of the APC pathway. Science 281(5382), 1509–1512 (1998).
  Medline CASGoogle Scholar
• 23. Saegusa M, Hashimura M, Kuwata T, Hamano M, Okayasu I. Beta-catenin simultaneously induces activation of the p53-p21WAF1 pathway and overexpression of cyclin D1 during squamous differentiation of endometrial carcinoma cells. Am. J. Pathol. 164(5), 1739–1749 (2004).
  Medline CASGoogle Scholar
• 24. Lapham A, Adams JE, Paterson A, Lee M, Brimmell M, Packham G.The Bcl-w promoter is activated by beta-catenin/TCF4 in human colorectal carcinoma cells. Gene 432(1-2), 112–117 (2009).
  Medline CASGoogle Scholar
• 25. Dow LE, O’Rourke KP, Simon J et al. Apc restoration promotes cellular differentiation and reestablishes crypt homeostasis in colorectal cancer. Cell 161(7), 1539–1552 (2015).
  Medline CASGoogle Scholar
• 26. Lin SY, Xia W, Wang JC et al. Beta-catenin, a novel prognostic marker for breast cancer: its roles in cyclin D1 expression and cancer progression. Proc. Natl Acad. Sci. USA 97(8), 4262–4266 (2000).
  Medline CASGoogle Scholar
• 27. Stewart DJ. Wnt signaling pathway in non-small cell lung cancer. J. Natl Cancer Inst. 106(1), djt356 (2014).
  MedlineGoogle Scholar
• 28. De La Coste A, Romagnolo B, Billuart P et al. Somatic mutations of the beta-catenin gene are frequent in mouse and human hepatocellular carcinomas. Proc. Natl Acad. Sci. USA 95(15), 8847–8851 (1998).
  MedlineGoogle Scholar
• 29. Luis TC, Ichii M, Brugman MH, Kincade P, Staal FJT. Wnt signaling strength regulates normal hematopoiesis and its deregulation is involved in leukemia development. Leukemia 26(3), 414–421 (2012).
  Medline CASGoogle Scholar
• 30. Sukhdeo K, Mani M, Zhang Y et al. Targeting the beta-catenin/TCF transcriptional complex in the treatment of multiple myeloma. Proc. Natl Acad. Sci. USA 104(18), 7516–7521 (2007).
  MedlineGoogle Scholar
• 31. Grootjans S, Berghe TV, Vandenabeele P. Initiation and execution mechanisms of necroptosis: an overview. Cell Death Differ. 24(7), 1184–1195 (2017).
  Medline CASGoogle Scholar
• 32. Malladi S, Macalinao DG, Jin X et al. Metastatic latency and immune evasion through autocrine inhibition of WNT. Cell 165(1), 45–60 (2016).
  Medline CASGoogle Scholar
• 33. Grasso CS, Giannakis M, Wells DK et al. Genetic mechanisms of immune evasion in colorectal cancer. Cancer Discov. 8(6), 730–749 (2018).
  Medline CASGoogle Scholar
• 34. Kramps T, Peter O, Brunner E et al. Wnt/wingless signaling requires BCL9/legless-mediated recruitment of pygopus to the nuclear beta-catenin–TCF complex. Cell 109(1), 47–60 (2002).
  Medline CASGoogle Scholar
• 35. Catrow JL, Zhang Y, Zhang M, Ji H. Discovery of selective small-molecule inhibitors for the β-catenin/T-cell factor protein–protein interaction through the optimization of the acyl hydrazone moiety. J. Med. Chem. 58(11), 4678–4692 (2015).
  Medline CASGoogle Scholar
• 36. Kahn M. Can we safely target the WNT pathway? Nat. Rev. Drug. Discov. 13(7), 513–532 (2014).
  Medline CASGoogle Scholar
• 37. Feng M, Jin JQ, Xia L et al. Pharmacological inhibition of β-catenin/BCL9 interaction overcomes resistance to immune checkpoint blockades by modulating T(reg) cells. Sci. Adv. 5(5), eaau5240 (2019).
  Medline CASGoogle Scholar
• 38. Zhong Z, Virshup DM. Wnt signaling and drug resistance in cancer. Mol. Pharmacol. 97(2), 72–89 (2020).
  Medline CASGoogle Scholar
• 39. Kawamoto SA, Thompson AD, Coleska A, Nikolovska-Coleska Z, Yi H, Wang S. Analysis of the interaction of BCL9 with beta-catenin and development of fluorescence polarization and surface plasmon resonance binding assays for this interaction. Biochemistry 48(40), 9534–9541 (2009).
  Medline CASGoogle Scholar
• 40. Willis TG, Zalcberg IR, Coignet LJ et al. Molecular cloning of translocation t(1;14)(q21;q32) defines a novel gene (BCL9) at chromosome 1q21. Blood 91(6), 1873–1881 (1998).
  Medline CASGoogle Scholar
• 41. Wang J, Zheng M, Zhu L et al. Low BCL9 expression inhibited ovarian epithelial malignant tumor progression by decreasing proliferation, migration, and increasing apoptosis to cancer cells. Cancer Cell Int. 19(1), 330 (2019).
  Medline CASGoogle Scholar
• 42. Polakis P. Drugging Wnt signalling in cancer. EMBO J. 31(12), 2737–2746 (2012).
  Medline CASGoogle Scholar
• 43. Gay DM, Ridgway RA, Müller M et al. Loss of BCL9/9l suppresses Wnt driven tumourigenesis in models that recapitulate human cancer. Nat. Commun. 10(1), 723 (2019).
  Medline CASGoogle Scholar
• 44. Mieszczanek J, Van Tienen LM, Ibrahim AEK, Winton DJ, Bienz M. Bcl9 and Pygo synergise downstream of Apc to effect intestinal neoplasia in FAP mouse models. Nat. Commun. 10(1),724 (2019).
  Medline CASGoogle Scholar
• 45. Xu W, Zhou W, Cheng M et al. Hypoxia activates Wnt/β-catenin signaling by regulating the expression of BCL9 in human hepatocellular carcinoma. Sci. Rep. 7, 40446 (2017).
  Medline CASGoogle Scholar
• 46. Mani M, Carrasco DE, Zhang Y et al. BCL9 promotes tumor progression by conferring enhanced proliferative, metastatic, and angiogenic properties to cancer cells. Cancer Res. 69(19), 7577–7586 (2009).
  Medline CASGoogle Scholar
• 47. Deka J, Wiedemann N, Anderle P et al. Bcl9/Bcl9l are critical for Wnt-mediated regulation of stem cell traits in colon epithelium and adenocarcinomas. Cancer Res. 70(16), 6619–6628 (2010).
  Medline CASGoogle Scholar
• 48. Sampietro J, Dahlberg CL, Cho US, Hinds TR, Kimelman D, Xu W. Crystal structure of a beta-catenin/BCL9/Tcf4 complex. Mol. Cell 24(2), 293–300 (2006). • Revealed the crystal structure of the β-catenin/BCL9 complex with moderate binding affinity and favorable binding area.
  Medline CASGoogle Scholar
• 49. De La Roche M, Worm J, Bienz M. The function of BCL9 in Wnt/beta-catenin signaling and colorectal cancer cells. BMC Cancer 8, 199 (2008).
  MedlineGoogle Scholar
• 50. Hoffmans R, Basler K. Identification and in vivo role of the Armadillo-Legless interaction. Development 131(17), 4393–4400 (2004).
  Medline CASGoogle Scholar
• 51. Hoffmans R, Basler K. BCL9-2 binds Arm/beta-catenin in a Tyr142-independent manner and requires Pygopus for its function in Wg/Wnt signaling. Mech. Dev. 124(1), 59–67 (2007).
  Medline CASGoogle Scholar
• 52. Hoggard LR, Zhang Y, Zhang M, Panic V, Wisniewski JA, Ji H. Rational design of selective small-molecule inhibitors for β-catenin/B-cell lymphoma 9 protein–protein interactions. J. Am. Chem. Soc. 137(38), 12249–12260 (2015).
  Medline CASGoogle Scholar
• 53. Wells JA, Mcclendon CL. Reaching for high-hanging fruit in drug discovery at protein–protein interfaces. Nature 450(7172), 1001–1009 (2007).
  Medline CASGoogle Scholar
• 54. Higueruelo AP, Jubb H, Blundell TL. Protein–protein interactions as druggable targets: recent technological advances. Curr. Opin. Pharmacol. 13(5), 791–796 (2013).
  Medline CASGoogle Scholar
• 55. Rezaei Araghi R, Keating AE. Designing helical peptide inhibitors of protein–protein interactions. Curr. Opin. Struct. Biol. 39, 27–38 (2016).
  MedlineGoogle Scholar
• 56. Nevola L, Giralt E. Modulating protein–protein interactions: the potential of peptides. Chem. Commun. (Camb.) 51(16), 3302–3315 (2015).
  Medline CASGoogle Scholar
• 57. Jiang ZY, Lu MC, You QD. Discovery and development of Kelch-like ECH-associated protein 1. nuclear factor erythroid 2-related factor 2 (KEAP1:NRF2) protein–protein interaction inhibitors: achievements, challenges, and future directions. J. Med. Chem. 59(24), 10837–10858 (2016).
  Medline CASGoogle Scholar
• 58. Blackwell HE, Grubbs RH. Highly efficient synthesis of covalently cross-linked peptide helices by ring-closing metathesis. Angew. Chem. Int. Ed. Engl. 37(23), 3281–3284 (1998).
  Medline CASGoogle Scholar
• 59. Schafmeister CE, Po J, Verdine GL. An all-hydrocarbon cross-linking system for enhancing the helicity and metabolic stability of peptides. J. Am. Chem. Soc. 122(24), 5891–5892 (2000).
  CASGoogle Scholar
• 60. Cromm PM, Spiegel J, Grossmann TN. Hydrocarbon stapled peptides as modulators of biological function. ACS Chem. Biol. 10(6), 1362–1375 (2015).
  Medline CASGoogle Scholar
• 61. Wójcik P, Berlicki Ł. Peptide-based inhibitors of protein–protein interactions. ACS Chem. Biol. 26(3), 707–713 (2016).
  CASGoogle Scholar
• 62. Walensky LD, Bird GH. Hydrocarbon-stapled peptides: principles, practice, and progress. J. Med. Chem. 57(15), 6275–6288 (2014).
  Medline CASGoogle Scholar
• 63. Chang YS, Graves B, Guerlavais V et al. Stapled α-helical peptide drug development: a potent dual inhibitor of MDM2 and MDMX for p53-dependent cancer therapy. Proc. Natl Acad. Sci. USA 110(36), E3445–E3454 (2013).
  Medline CASGoogle Scholar
• 64. Kawamoto SA, Coleska A, Ran X, Yi H, Yang C-Y, Wang S. Design of triazole-stapled BCL9 α-helical peptides to target the β-catenin/B-cell CLL/lymphoma 9 (BCL9) protein–protein interaction. J. Med. Chem. 55(3), 1137–1146 (2012).
  Medline CASGoogle Scholar
• 65. Takada K, Zhu D, Bird GH et al. Targeted disruption of the BCL9/β-catenin complex inhibits oncogenic Wnt signaling. Sci. Transl. Med. 4(148), 148ra117 (2012).
  MedlineGoogle Scholar
• 66. Kasper MA, Glanz M, Oder A, Schmieder P, von Kries JP, Hackenberger CPR. Vinylphosphonites for Staudinger-induced chemoselective peptide cyclization and functionalization. Chem. Sci. 10(25), 6322–6329 (2019).
  Medline CASGoogle Scholar
• 67. Ross NT, Katt WP, Hamilton AD. Synthetic mimetics of protein secondary structure domains. Philos. Trans. A Math. Phys. Eng. Sci. 368(1914), 989–1008 (2010).
  Medline CASGoogle Scholar
• 68. Sang P, Zhang M, Shi Y et al. Inhibition of β-catenin/B cell lymphoma 9 protein–protein interaction using α-helix-mimicking sulfono-γ-AApeptide inhibitors. Proc. Natl Acad. Sci. USA 116(22), 10757–10762 (2019).
  Medline CASGoogle Scholar
• 69. Moreira IS, Fernandes PA, Ramos MJ. Hot spots – a review of the protein–protein interface determinant amino-acid residues. Proteins 68(4), 803–812 (2007).
  Medline CASGoogle Scholar
• 70. Clackson T, Wells JA. A hot spot of binding energy in a hormone–receptor interface. Science 267(5196), 383–386 (1995).
  Medline CASGoogle Scholar
• 71. Reichmann D, Rahat O, Cohen M, Neuvirth H, Schreiber G. The molecular architecture of protein–protein binding sites. Curr. Opin. Struct. Biol. 17(1), 67–76 (2007).
  Medline CASGoogle Scholar
• 72. Wisniewski JA, Yin J, Teuscher KB, Zhang M, Ji H. Structure-based design of 1,4-dibenzoylpiperazines as β-catenin/B-cell lymphoma 9 protein–protein interaction inhibitors. ACS Med. Chem. Lett. 7(5), 508–513 (2016).
  Medline CASGoogle Scholar
• 73. Zhang M, Wang Z, Zhang Y, Guo W, Ji H. Structure-based optimization of small-molecule inhibitors for the β-catenin/B-cell lymphoma 9 protein–protein interaction. J. Med. Chem. 61(7), 2989–3007 (2018).
  Medline CASGoogle Scholar
• 74. De La Roche M, Rutherford TJ, Gupta D et al. An intrinsically labile α-helix abutting the BCL9-binding site of β-catenin is required for its inhibition by carnosic acid. Nat. Commun. 3, 680 (2012).
  MedlineGoogle Scholar
• 75. Baell J, Walters MA. Chemistry: chemical con artists foil drug discovery. Nature 513(7519), 481–483 (2014).
  Medline CASGoogle Scholar
• 76. Jochim AL, Arora PS. Assessment of helical interfaces in protein–protein interactions. Mol. Biosyst. 5(9), 924–926 (2009).
  Medline CASGoogle Scholar
• 77. Baell JB, Holloway GA. New substructure filters for removal of pan assay interference compounds (PAINS) from screening libraries and for their exclusion in bioassays. J. Med. Chem. 53(7), 2719–2740 (2010).
  Medline CASGoogle Scholar
• 78. Kane CD, Stevens KA, Fischer JE et al. Molecular characterization of novel and selective peroxisome proliferator-activated receptor alpha agonists with robust hypolipidemic activity in vivo. Mol. Pharmacol. 75(2), 296–306 (2009).
  Medline CASGoogle Scholar
• 79. Zhang M, Wisniewski JA, Ji H. AlphaScreen selectivity assay for β-catenin/B-cell lymphoma 9 inhibitors. Anal. Biochem. 469, 43–53 (2015).
  Medline CASGoogle Scholar
• 80. Mullard A. Protein–protein interaction inhibitors get into the groove. Nat. Rev. Drug. Discov. 11(3), 173–175 (2012).
  Medline CASGoogle Scholar
• 81. Wang Z, Li Z, Ji H. Direct targeting of β-catenin in the Wnt signaling pathway: current progress and perspectives. Med. Res. Rev. doi:10.1002/med.21787 (2021) (Epub ahead of print).
  Google Scholar